| Description |
1 online resource |
| Series |
Cancer etiology, diagnosis and treatments |
|
Cancer etiology, diagnosis, and treatments.
|
| Contents |
TARGETED THERAPIES IN CANCER AN UPDATE ; TARGETED THERAPIES IN CANCER AN UPDATE ; Contents ; Preface ; Abbreviations ; Chapter 1 Innovation in the Biopharmaceutical Pipeline ; Abstract ; Introduction ; Drug Discovery and Development Process ; Discovery and Preclinical Testing ; Clinical Testing in Human Subjects ; Regulatory Review and Approval ; Post-Approval Research and Monitoring ; References ; Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA ; Abstract ; Introduction ; 1. Tyrosine Kinase (TK) Inhibitors (TKIs) |
|
2. Serine/Threonine Kinase Inhibitors (STKIs) 3. Dual Specificity Kinase Inhibitors (DSKIs) ; 4. Lipid Kinase Inhibitors (LKIs) ; 5. Poly ADP Ribose Polymerase (PARP) Inhibitors (PARPIs) ; 6. Monoclonal Antibodies (mAbs) ; 7. Microtubule Targeting Agents (MTAs) ; 8. Histone Deacetylase (HDAC) Inhibitors ; 9. Proteasome Inhibitors ; 10. Antimetabolites; 11. Immunomodulatory Agents (iMiDs) ; 12. DNA Methyltransferase Inhibitors ; 13. Hedgehog Pathway Inhibitor ; 14. Enzymes ; 15. Hormone (Androgen Deprivation) Therapy ; 16. Decoy Vascular Endothelial Growth Factor Receptor |
|
17. Protein Translation Inhibitor 18. Somatostatin (SST) Analogue ; 19. Autologous Cellular Immunotherapy (Vaccine) ; 20. Oncolytic Virus ; 21. Alkylating Agent ; 22. Radiopharmaceutical Compound ; References ; Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA ; Abstract ; Introduction ; Reference ; Chapter 4 Targeted Therapies: Detailed Description ; Abstract ; Introduction ; Rituximab (Rituxan®) ; Trastuzumab (Herceptin®) ; Imatinib (Gleevec® -US- or Glivec® -EU-) ; Alemtuzumab (Campath®) ; Ibritumomab Tiuxetan (Zevalin®) ; Gefitinib (Iressa®) |
|
Tositumomab (Bexxar®) Azacitidine (Arzerra®) ; Pemetrexed (Alimta®) ; Cetuximab (Erbitux®) ; Bevacizumab (Avastin®) ; Erlotinib (Tarceva®) ; Nelarabine (Arranon®) ; Sorafenib (Nexavar®) ; Pegaspargase (Oncospar®) ; Lenalidomide (Revlimid®) ; Sunitinib (Sutent®) ; Dasatinib (Sprycel®) ; Panitumumab (Vectibix®) ; Vorinostat (Zolinza®) ; Bortezomib (Velcade®) ; Decitabine (Dacogen®) ; Lapatinib (Tykerb®) ; Temsirolimus (Torisel®) ; Ixabepilone (Ixempra®) ; Nilotinib (Tasigna®) ; Degarelix (Firmagon®) ; Everolimus (Afinitor®) ; Pralatrexate (Folotyn®) ; Pazopanib (Votrient®) |
|
Ofatumumab (Arzerra®) Romidepsin (Istodax®) ; Cabazitaxel (Jevtana®) ; Sipuleucel-T (Provenge®) ; Eribulin Mesylate (Halaven®) ; Denosumab (Xgeva®) ; Ipilimumab (Yervoy®) ; Vandetanib (Caprelsa®) ; Abiraterone Acetate (Zytiga®) ; Vemurafenib (Zelboraf®) ; Brentuximab Vedotin (Adcetris®) ; Crizotinib (Xalkori®) ; Ruxolitinib (Jakafi®) ; Asparaginase Erwinia Chrysanthemi (Erwinaze®) ; Axitinib (Inlyta®) ; Vismodegib (Erivedge®) ; Pertuzumab (Perjeta®) ; Carfilzomib (Kyprolis®) ; Ziv-Aflibercept (Zaltrap®) ; Enzalutamide (Xtandi®) ; Bosutinib (Bosulif®) ; Regorafenib (Stivarga®) |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Description based on print version record |
| Subject |
Cancer -- Chemotherapy.
|
|
Precision medicine
|
|
Cancer -- Treatment.
|
|
Neoplasms -- drug therapy
|
|
Precision Medicine
|
|
HEALTH & FITNESS / Diseases / General
|
|
MEDICAL / Clinical Medicine
|
|
MEDICAL / Diseases
|
|
MEDICAL / Evidence-Based Medicine
|
|
MEDICAL / Internal Medicine
|
|
Cancer -- Treatment
|
|
Cancer -- Chemotherapy
|
|
Precision medicine
|
| Form |
Electronic book
|
| LC no. |
2020676217 |
| ISBN |
9781634847704 |
|
1634847709 |
|
